ライフサイエンスコーパス: neuromyelitis optica

1 of CNS inflammation and astrocytic injury in neuromyelitis optica.

2 le, 207 clinically isolated syndrome and six neuromyelitis optica.

3 the neuroinflammatory demyelinating disease neuromyelitis optica.

4 a postrema may be a first point of attack in neuromyelitis optica.

5 id antibody syndrome, myasthenia gravis, and neuromyelitis optica.

6 ith multiple sclerosis and optic neuritis in neuromyelitis optica.

7 demyelination, and necrosis that is seen in neuromyelitis optica.

8 s distinguish it from multiple sclerosis and neuromyelitis optica.

9 nostaining is detectable in early lesions of neuromyelitis optica.

10 ncorporated into new diagnostic criteria for neuromyelitis optica.

11 l multiple sclerosis seems to be the same as neuromyelitis optica.

12 cephalomyelitis, Guillain-Barre syndrome and neuromyelitis optica.

13 ple sclerosis, autoimmune encephalitides and neuromyelitis optica.

14 itudinal myelopathy outside of BD, including neuromyelitis optica.

15 toimmunity, including multiple sclerosis and neuromyelitis optica.

16 concurrent AQP4 antibodies had conversion to neuromyelitis optica.

17 ents, none of whom had multiple sclerosis or neuromyelitis optica.

18 be recognized as rare presenting features of neuromyelitis optica.

19 Of the 48 controls with neuromyelitis optica, 37 (77%) had AQP4 antibodies, 4 (8

20 many recurrent cases who also have myelitis (neuromyelitis optica) a serum antibody to aquaporin-4 wa

21 oantibodies were discovered in patients with neuromyelitis optica, a demyelinating disease, and are n

22 this treatment, and it consistently worsens neuromyelitis optica, a disease similar to RRMS.

23 , relapsing-remitting multiple sclerosis and neuromyelitis optica, a high proportion of cells express

24 ous system inflammatory disorders, including neuromyelitis optica, acute disseminated encephalomyelit

25 ary tests, such as diagnostic antibodies for neuromyelitis optica, allows better phenotyping of the h

26 Neuromyelitis optica (also known as Devic's disease) is

27 nts with optic neuritis, multiple sclerosis, neuromyelitis optica, Alzheimer disease, and Parkinson d

28 imaging of the retina in multiple sclerosis, neuromyelitis optica, Alzheimer disease, and Parkinson d

29 We review recent advances in neuromyelitis optica, an idiopathic inflammatory demyeli

30 were 73% (95% CI 60-86) and 91% (79-100) for neuromyelitis optica and 58% (30-86) and 100% (66-100) f

31 all patient groups investigated, those with neuromyelitis optica and a history of optic neuritis exh

32 lassical multiple sclerosis and both Devic's neuromyelitis optica and acute disseminated encephalomye

33 aware of the uncommon presenting features of neuromyelitis optica and associated autoimmune condition

34 NMO-IgG is a specific marker autoantibody of neuromyelitis optica and binds at or near the blood-brai

35 mmunoglobulin G, is strongly associated with neuromyelitis optica and identifies patients with severe

36 Objective Neuromyelitis optica and its spectrum disorders (NMOSD)

37 ple sclerosis (n = 31) recruited from Oxford neuromyelitis optica and multiple sclerosis clinical ser

38 to be explored further in future prospective neuromyelitis optica and neuromyelitis optica spectrum d

39 Previous clinical neuromyelitis optica and neuromyelitis optica spectrum d

40 rtant implications for interpreting clinical neuromyelitis optica and neuromyelitis optica spectrum d

41 Neuromyelitis optica and neuromyelitis optica spectrum d

42 uggest a new strategy for neuroprotection in neuromyelitis optica and related diseases.

43 euromyelitis optica (NMO-IgG) to distinguish neuromyelitis optica and related disorders from multiple

44 sion, facilitated the ability to distinguish neuromyelitis optica and related syndromes from typical

45 reproduces the key histological features of neuromyelitis optica and that aquaporin-4 is necessary a

46 several other indications, such as uveitis, neuromyelitis optica and, most recently, COVID-19 pneumo

47 7% acute disseminated encephalomyelitis, 7% neuromyelitis optica), and 91% received treatment (85% s

48 ls (30 healthy individuals, 48 patients with neuromyelitis optica, and 64 patients with multiple scle

49 ses such as systemic lupus erythematosus and neuromyelitis optica, and can lead to transient or perma

50 et for such disorders as multiple sclerosis, neuromyelitis optica, and CD4(+) T cell-mediated disorde

51 sms of acute disseminated encephalomyelitis, neuromyelitis optica, and classical multiple sclerosis.

52 tion and inflammation in multiple sclerosis, neuromyelitis optica, and in experimental autoimmune enc

53 immunity is prominent in multiple sclerosis, neuromyelitis optica, and the paraneoplastic syndromes w

54 sition verifies that astrocytic reactions in neuromyelitis optica are not solely dependent on IgG-med

55 P4 was labeled with a monoclonal recombinant neuromyelitis optica autoantibody.

56 whether patients with multiple sclerosis or neuromyelitis optica develop retinal neuronal layer path

57 ed according to 2015 International Panel for Neuromyelitis Optica Diagnosis criteria, who had an Expa

58 To identify independent predictors of neuromyelitis optica diagnosis, after assessing the prev

59 after vomiting onset), 7 patients fulfilled neuromyelitis optica diagnostic criteria.

60 Devic's neuromyelitis optica (DNO) is a demyelinating syndrome t

61 ine]) supported the alternative diagnosis of neuromyelitis optica for 2 patients as seropositive by b

62 body marker (NMO-IgG) further differentiates neuromyelitis optica from multiple sclerosis and has hel

63 unoglobulin G (NMO-IgG), which distinguishes neuromyelitis optica from multiple sclerosis.

64 It distinguishes neuromyelitis optica from multiple sclerosis.

65 ble imaging features can help to distinguish neuromyelitis optica from multiple sclerosis.

66 ologic, and immunologic features distinguish neuromyelitis optica from other severe cases of multiple

67 Neuromyelitis optica has a worldwide distribution, poor

68 The recent identification of neuromyelitis optica-IgG, a novel marker of neuromyeliti

69 e-based assays using sera from patients with neuromyelitis optica, immune mouse serum, and Abs raised

70 ecently identified serum antibody biomarker, neuromyelitis optica immunoglobulin G (NMO-IgG), which d

71 A specific serum biomarker, neuromyelitis optica immunoglobulin G, is strongly assoc

72 Neuromyelitis optica-immunoglobulin G (NMO-IgG) binds to

73 Neuromyelitis optica is a chronic neuroinflammatory dise

74 Neuromyelitis optica is a paradigmatic autoimmune diseas

75 Neuromyelitis optica is a rare neurological autoimmune d

76 Neuromyelitis optica is an autoimmune inflammatory disor

77 Neuromyelitis optica is an inflammatory demyelinating di

78 Neuromyelitis optica is an inflammatory demyelinating di

79 Neuromyelitis optica is an inflammatory demyelinating di

80 Neuromyelitis optica is associated with severe neurodisa

81 The neuroinflammatory demyelinating disease neuromyelitis optica is marked by pathogenic autoantibod

82 Neuromyelitis optica is the most severe of these disorde

83 g an early and primary event in the evolving neuromyelitis optica lesion.

84 nsformation also readily detectable in human neuromyelitis optica lesions, which especially affected

85 damaged, and how circulating AQP4-IgG enters neuromyelitis optica lesions.

86 water channel aquaporin-4, which is lost in neuromyelitis optica lesions.

87 ly the disease pattern does not resemble the neuromyelitis optica-like disease observed in mice beari

88 tica patients with human complement produced neuromyelitis optica-like lesions in mice.

89 e autoimmune response against aquaporin-4 in neuromyelitis optica may be triggered by infection-induc

90 Most patients with neuromyelitis optica (NMO) and many with NMO spectrum di

91 Neuromyelitis optica (NMO) and multiple sclerosis (MS) a

92 b was detected in three; two presenting with neuromyelitis optica (NMO) and one with isolated optic n

93 quaporin 4 (AQP4)-specific autoantibodies in neuromyelitis optica (NMO) are immunoglobulin (Ig)G1, a

94 Neuromyelitis optica (NMO) attacks often are severe, are

95 P4) water channel-specific IgG distinguishes neuromyelitis optica (NMO) from multiple sclerosis and c

96 Neuromyelitis optica (NMO) has been described as a disea

97 Neuromyelitis optica (NMO) has long been considered as a

98 75%) were positive and 12 (25%) negative for neuromyelitis optica (NMO) IgG (per IIF of serial serum

99 We investigated whether neuromyelitis optica (NMO) IgG seropositivity at the ini

100 Neuromyelitis optica (NMO) is a central nervous system (

101 Neuromyelitis optica (NMO) is a chronic inflammatory dis

102 Neuromyelitis optica (NMO) is a neuroinflammatory diseas

103 Neuromyelitis Optica (NMO) is a severe and rare inflamma

104 Neuromyelitis optica (NMO) is a severe autoimmune inflam

105 Neuromyelitis optica (NMO) is a severe inflammatory CNS

106 Neuromyelitis optica (NMO) is an autoimmune CNS disorder

107 Neuromyelitis optica (NMO) is an autoimmune disease of t

108 Neuromyelitis optica (NMO) is an autoimmune disease of t

109 Neuromyelitis optica (NMO) is an autoimmune disease of t

110 Neuromyelitis Optica (NMO) is an autoimmune disease with

111 Neuromyelitis optica (NMO) is an autoimmune inflammatory

112 Neuromyelitis optica (NMO) is an inflammatory demyelinat

113 Neuromyelitis optica (NMO) is an inflammatory demyelinat

114 Neuromyelitis optica (NMO) is an inflammatory demyelinat

115 Neuromyelitis optica (NMO) is an inflammatory demyelinat

116 Neuromyelitis optica (NMO) is an inflammatory demyelinat

117 Neuromyelitis optica (NMO) is an inflammatory demyelinat

118 Neuromyelitis optica (NMO) is an inflammatory demyelinat

119 Neuromyelitis optica (NMO) is an inflammatory demyelinat

120 Neuromyelitis optica (NMO) is an inflammatory demyelinat

121 Neuromyelitis optica (NMO) is an inflammatory disease of

122 Neuromyelitis optica (NMO) is caused by binding of patho

123 Neuromyelitis optica (NMO) is characterized by disabling

124 Neuromyelitis optica (NMO) is characterized by the prese

125 Aquaporin 4 antibody-negative neuromyelitis optica (NMO) is rare when good assays are

126 rosis is a prominent pathological feature of neuromyelitis optica (NMO) lesions and is clinically rel

127 Coded samples from patients with neuromyelitis optica (NMO) or NMOSD (101) and controls (

128 cells are thought to have a central role in neuromyelitis optica (NMO) pathogenesis.

129 in-4 (AQP4)-specific T cells are expanded in neuromyelitis optica (NMO) patients and exhibit Th17 pol

130 The serum of most neuromyelitis optica (NMO) patients contains autoantibod

131 T cells from neuromyelitis optica (NMO) patients, which recognize the

132 epeated rituximab treatment in patients with neuromyelitis optica (NMO) revealed significant improvem

133 ceded or followed by independent episodes of neuromyelitis optica (NMO) spectrum disorder (5 cases, 4

134 segments) is considered noncharacteristic of neuromyelitis optica (NMO) spectrum disorders (NMOSDs).

135 rosis (MS), anti-aquaporin-4 (AQP4)-negative neuromyelitis optica (NMO), and chronic relapsing inflam

136 emblance the disease shows pathologically to neuromyelitis optica (NMO), including that demyelination

137 ere divided in 5 different groups: controls, neuromyelitis optica (NMO), longitudinally extensive tra

138 unified by detection of the serum biomarker neuromyelitis optica (NMO)-IgG.

139 Neuromyelitis optica (NMO)-immunoglobulin G (IgG) is a c

140 ptic neuritis is a cardinal manifestation of neuromyelitis optica (NMO).

141 ant in inflammatory demyelinating lesions in neuromyelitis optica (NMO).

142 nerve and spinal cord pathologic changes in neuromyelitis optica (NMO).

143 exacerbates MS, and it consistently worsens neuromyelitis optica (NMO).

144 rin-4 (AQP4) are thought to be pathogenic in neuromyelitis optica (NMO).

145 y specific for the neuroinflammatory disease neuromyelitis optica (NMO).

146 s and an update on the current management of neuromyelitis optica (NMO).

147 rodegeneration and autoimmune disorders like neuromyelitis optica (NMO).

148 diseases such as multiple sclerosis (MS) and neuromyelitis optica (NMO).

149 is (MS), intracerebral hemorrhage (ICH), and neuromyelitis optica (NMO).

150 ntal autoimmune encephalomyelitis (EAE), and neuromyelitis optica (NMO).

151 has come into focus for its association with neuromyelitis optica (NMO).

152 Devic's disease [neuromyelitis optica (NMO)] is an idiopathic inflammator

153 sessed the capacity of a putative marker for neuromyelitis optica (NMO-IgG) to distinguish neuromyeli

154 Neuromyelitis optica (NMO; also known as Devic syndrome)

155 ogenesis of both multiple sclerosis (MS) and neuromyelitis optica (NMOSD).

156 sitive cases identified incidentally, 12 had neuromyelitis optica or a high-risk syndrome for the dis

157 amples from 102 North American patients with neuromyelitis optica or with syndromes that suggest high

158 nction were more likely to meet criteria for neuromyelitis optica (P = 0.04) and were also more likel

159 ly in 98 multiple sclerosis participants, 22 neuromyelitis optica participants and 72 healthy control

160 Typical brain lesions occurred in 50.9% of neuromyelitis optica patients (18.1% brainstem periventr

161 es, mice injected with immunoglobulin G from neuromyelitis optica patients and human complement into

162 n 12 h of co-injecting immunoglobulin G from neuromyelitis optica patients and human complement, ther

163 Immunoglobulin G from neuromyelitis optica patients did not activate mouse com

164 In our mouse model, immunoglobulin G from neuromyelitis optica patients does not require pre-exist

165 Neuromyelitis optica patients harbour autoantibodies aga

166 lin G from aquaporin-4-autoantibody-positive neuromyelitis optica patients has the potential to damag

167 Although up to 50% of neuromyelitis optica patients have no typical lesions an

168 sions along lateral ventricles discriminated neuromyelitis optica patients in both training (sensitiv

169 ently been reported that immunoglobulin from neuromyelitis optica patients injected peripherally does

170 utely ill multiple sclerosis patient and two neuromyelitis optica patients revealed instances of infi

171 ary and sufficient for immunoglobulin G from neuromyelitis optica patients to exert its effect.

172 wever, co-injection of immunoglobulin G from neuromyelitis optica patients with human complement prod

173 e that co-injection of immunoglobulin G from neuromyelitis optica patients with human complement repr

174 mice that received immunoglobulin G from non-neuromyelitis optica patients with human complement, or

175 ull mice that received immunoglobulin G from neuromyelitis optica patients with human complement.

176 were unchanged in primary progressive MS and neuromyelitis optica patients.

177 gut of patients with multiple sclerosis and neuromyelitis optica provides evidence of communication

178 uropathy, optic neuritis/multiple sclerosis, neuromyelitis optica, pseudotumor cerebri, migraine, opt

179 neurodegeneration in multiple sclerosis and neuromyelitis optica, regardless of disease stage.

180 ng diseases (i.e., multiple sclerosis versus neuromyelitis optica) represents distinct syndromes.

181 t AQP4-IgG is involved in the development of neuromyelitis optica revolutionised our understanding of

182 scriptions of astrocytic lesions reported in neuromyelitis optica so far have emphasized a characteri

183 tity of autoimmune AQP4 myopathy extends the neuromyelitis optica spectrum beyond the central nervous

184 , 29%), multiple sclerosis (MS) (n = 4,14%), neuromyelitis optica spectrum disease (NMOSD) (n = 3, 11

185 d predicted MOG-antibody disease versus AQP4-neuromyelitis optica spectrum disorder (accuracy: 76%, s

186 sease (MOGAD) (92), aquaporin-4-IgG-positive neuromyelitis optica spectrum disorder (AQP4+NMOSD) (75)

187 s with aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder (AQP4-IgG+ NMOSD)

188 ment monitoring; but in aquaporin-4 antibody neuromyelitis optica spectrum disorder (AQP4-NMOSD), the

189 0) before and after treatment, patients with neuromyelitis optica spectrum disorder (n = 87), MOG ant

190 I) and T helper 17 (TH17) drive pathology in neuromyelitis optica spectrum disorder (NMOSD) and in TH

191 Multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD) and myeli

192 -aquaporin-4-antibody (AQP4-Ab)-seronegative neuromyelitis optica spectrum disorder (NMOSD) and relat

193 ittle is known about the association between neuromyelitis optica spectrum disorder (NMOSD) and the r

194 Background Patients with neuromyelitis optica spectrum disorder (NMOSD) are often

195 Neuromyelitis optica spectrum disorder (NMOSD) can be ca

196 lerosis, and aquaporin-4 antibody-associated neuromyelitis optica spectrum disorder (NMOSD) cumulativ

197 Neuromyelitis optica spectrum disorder (NMOSD) dispropor

198 is a pathoanatomical feature differentiating neuromyelitis optica spectrum disorder (NMOSD) from mult

199 Neuromyelitis optica spectrum disorder (NMOSD) is a CNS

200 Neuromyelitis optica spectrum disorder (NMOSD) is a rare

201 Neuromyelitis optica spectrum disorder (NMOSD) is an aut

202 Neuromyelitis optica spectrum disorder (NMOSD) is an aut

203 ics of ring-enhancing spinal cord lesions in neuromyelitis optica spectrum disorder (NMOSD) myelitis

204 is a common and debilitating consequence of neuromyelitis optica spectrum disorder (NMOSD) myelitis,

205 Reports of neuromyelitis optica spectrum disorder (NMOSD) occurring

206 Approximately 80% of neuromyelitis optica spectrum disorder (NMOSD) patients

207 ive agent (IS) which is widely prescribed in neuromyelitis optica spectrum disorder (NMOSD) patients.

208 reduced the risk of relapse in patients with neuromyelitis optica spectrum disorder (NMOSD) when adde

209 No approved therapies exist for neuromyelitis optica spectrum disorder (NMOSD), a rare,

210 AQP4-IgG was cloned from a patient with neuromyelitis optica spectrum disorder (NMOSD), an autoi

211 ntation at onset of multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), and myel

212 Neuromyelitis optica spectrum disorder (NMOSD), myelin o

213 ively, in CSF from people with untreated MS, neuromyelitis optica spectrum disorder (NMOSD), other in

214 h anti-aquaporin-4 antibody-positive (AQP4+) neuromyelitis optica spectrum disorder (NMOSD).

215 n the pathogenesis of brain tissue damage in neuromyelitis optica spectrum disorder (NMOSD).

216 first-line treatment to prevent relapses of neuromyelitis optica spectrum disorder (NMOSD).

217 Patients with MOG-IgG had neuromyelitis optica spectrum disorder (NMOSD, n=10), id

218 ears, median EDSS: 2 (0-7.5)], 162 with AQP4-neuromyelitis optica spectrum disorder [132 females, mea

219 ses in which demyelination is a feature (eg, neuromyelitis optica spectrum disorder and acute dissemi

220 ases with an autoantibody component, such as neuromyelitis optica spectrum disorder and autoimmune en

221 nical and MRI features when compared to AQP4-neuromyelitis optica spectrum disorder and multiple scle

222 ere: diagnosis of MOG-antibody disease; AQP4-neuromyelitis optica spectrum disorder and multiple scle

223 tions, such as systemic lupus erythematosus, neuromyelitis optica spectrum disorder and myasthenia gr

224 Overall, 63 adjudicated neuromyelitis optica spectrum disorder attacks occurred

225 rial, adults aged 18 years and older with an neuromyelitis optica spectrum disorder diagnosis, Expand

226 ge the therapeutic landscape for people with neuromyelitis optica spectrum disorder in different ways

227 ntibody, demonstrated safety and efficacy in neuromyelitis optica spectrum disorder in the randomised

228 Neuromyelitis optica spectrum disorder is an autoimmune

229 Although the prevalence of neuromyelitis optica spectrum disorder is limited to aro

230 e non-Hispanic patients with MS reveals that neuromyelitis optica spectrum disorder is rarely misdiag

231 nd spinal cord scans were evaluated from 116 neuromyelitis optica spectrum disorder patients (98 sero

232 Previous clinical neuromyelitis optica and neuromyelitis optica spectrum disorder studies have incl

233 terpreting clinical neuromyelitis optica and neuromyelitis optica spectrum disorder studies, since cl

234 future prospective neuromyelitis optica and neuromyelitis optica spectrum disorder studies.

235 lizumab, and inebilizumab) for patients with neuromyelitis optica spectrum disorder that all showed a

236 was identified in 3 of 50 patients (6%) with neuromyelitis optica spectrum disorder, 5 of 228 patient

237 WHERE NEXT?: Despite the rarity of neuromyelitis optica spectrum disorder, a relative abund

238 These syndromes include neuromyelitis optica spectrum disorder, acute disseminat

239 -seropositive, aged at least 18 years, had a neuromyelitis optica spectrum disorder, and had at least

240 e drugs used as DMTs for multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune

241 n drugs used as DMTs for multiple sclerosis, neuromyelitis optica spectrum disorder, and other immune

242 In neuromyelitis optica spectrum disorder, cases with a his

243 c inflammatory myopathy, systemic sclerosis, neuromyelitis optica spectrum disorder, myasthenia gravi

244 ment of individuals with multiple sclerosis, neuromyelitis optica spectrum disorder, or myelin oligod

245 m inebilizumab treatment in individuals with neuromyelitis optica spectrum disorder, which supports t

246 e in real-world populations of patients with neuromyelitis optica spectrum disorder.

247 frequent myelitis, findings compatible with neuromyelitis optica spectrum disorder.

248 zumab as a CD19+ B-cell-depleting therapy in neuromyelitis optica spectrum disorder.

249 lycoprotein antibody-associated disease, and neuromyelitis optica spectrum disorder.

250 n-4 were positive, leading to a diagnosis of neuromyelitis optica spectrum disorder.

251 assify patients as MOG-antibody disease/AQP4-neuromyelitis optica spectrum disorder/multiple sclerosi

252 ing conditions such as multiple sclerosis or neuromyelitis optica spectrum disorder; systemic disease

253 aluated in aquaporin-4 antibody seropositive neuromyelitis optica spectrum disorders (AQP4+NMOSD).

254 to be lower than in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders (AQP4-IgG+NMOSDs

255 neuromyelitis optica-IgG, a novel marker of neuromyelitis optica spectrum disorders (including longi

256 Neuromyelitis optica spectrum disorders (NMOSD) are a ty

257 Neuromyelitis optica spectrum disorders (NMOSD) can pres

258 Neuromyelitis optica spectrum disorders (NMOSD) comprise

259 Neuromyelitis optica spectrum disorders (NMOSD) constitu

260 ppearing white matter (NAWM) is preserved in neuromyelitis optica spectrum disorders (NMOSD) is open

261 Optic neuritis (ON) in neuromyelitis optica spectrum disorders (NMOSD) regularl

262 In neuromyelitis optica spectrum disorders (NMOSD) thalamic

263 mation contributes to acute demyelination in neuromyelitis optica spectrum disorders (NMOSD).

264 on are critical in the immunopathogenesis of neuromyelitis optica spectrum disorders (NMOSD).

265 uaporin (AQP) 4 antibody (AQP4-Ab) assays in neuromyelitis optica spectrum disorders (NMOSD).

266 Importance: Neuromyelitis optica spectrum disorders (NMOSDs) are aut

267 Neuromyelitis optica spectrum disorders (NMOSDs) are cau

268 quaporin-4 antibody seropositive (AQP4-IgG+) neuromyelitis optica spectrum disorders (NMOSDs) frequen

269 We have undertaken a clinic-based survey of neuromyelitis optica spectrum disorders (NMOSDs) in Aust

270 l cord is commonly involved in patients with neuromyelitis optica spectrum disorders (NMOSDs).

271 ility in patients with multiple sclerosis or neuromyelitis optica spectrum disorders (NMOSDs).

272 sclerosis (MS) and to aquaporin-4 (AQP4) in neuromyelitis optica spectrum disorders (NMOSDs).

273 ic neuritis (20 [17%]), myelitis (13 [11%]), neuromyelitis optica spectrum disorders (six [5%]), and

274 ng atypical multiple sclerosis, seronegative neuromyelitis optica spectrum disorders and relapsing ac

275 Neuromyelitis optica and neuromyelitis optica spectrum disorders have been recent

276 e MS n = 9; secondary progressive MS n = 10; neuromyelitis optica spectrum disorders n = 15; and othe

277 onset age, onset phenotype and ethnicity on neuromyelitis optica spectrum disorders outcomes.

278 Conclusion In participants with neuromyelitis optica spectrum disorders, focal areas of

279 ffecting humans, such as multiple sclerosis, neuromyelitis optica spectrum disorders, Parkinson disea

280 he MRI criteria for multiple sclerosis (e.g. neuromyelitis optica spectrum disorders, Susac syndrome)

281 In multiple sclerosis and neuromyelitis optica spectrum disorders, T cells destroy

282 at neutralises the complement protein C5--in neuromyelitis optica spectrum disorders.

283 ability measures in patients with aggressive neuromyelitis optica spectrum disorders.

284 glycoprotein were, as expected, specific for neuromyelitis optica spectrum disorders.

285 ry aquaporin 4-immunoglobulin G-seropositive neuromyelitis optica spectrum disorders.

286 s are associated with relapsing inflammatory neuromyelitis optica spectrum disorders.

287 organs beyond the central nervous system in neuromyelitis optica spectrum disorders.

288 ng for this biomarker has suggested that the neuromyelitis optica spectrum is broader than previously

289 ultiple sclerosis and has helped to define a neuromyelitis optica spectrum of disorders.

290 nd differences from aquaporin-4-IgG-positive-neuromyelitis-optica-spectrum-disorder (AQP4+NMOSD), and

291 Neuromyelitis optica, systemic lupus erythematous, neuro

292 ct form of immune-mediated axon pathology in neuromyelitis optica that mechanistically differs from k

293 The relation of neuromyelitis optica to optic-spinal multiple sclerosis

294 Its presence and specificity for neuromyelitis optica was confirmed in diverse population

295 ce 2005) whose initial presenting symptom of neuromyelitis optica was intractable vomiting.

296 Patients with neuromyelitis optica who have aquaporin-4 antibodies are

297 exact role of NMO-IgG in the pathogenesis of neuromyelitis optica will provide a foundation for ratio

298 This report highlights the association of neuromyelitis optica with dermatitis herpetiformis, whic

299 ith multiple sclerosis and participants with neuromyelitis optica, with and without a history of opti

300 articipants with multiple sclerosis and with neuromyelitis optica without a history of optic neuritis